Since my first days of learning about Low Dose Naltrexone (LDN) as a medical student to now–nearly 15 years later as a licensed physician–I have witnessed this safe, non-toxic, and inexpensive drug help thousands of patients find an answer to their health issues. The more published research I come across, it’s clear that I am not alone.
Earlier this year, MedScape published an insightful article combining the experiences of various physicians all across the world reporting positive outcomes for patients with a variety of conditions using LDN. Specifically, the article cites two major sources reflecting similar successes my patients have reported: the BMJ Case Reports and a Norway documentary entitled ‘Our Small Country.’
BMJ Case Reports: These 2020 reports cite patient stories of LDN usage to relieve joint pain, fatigue, cognitive impairment, and post-exertional malaise in patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). As stated in the article, “responses to LDN varied from a ‘life-changing’ full recovery of function to partial improvements in pain and sleep.”
Norway Documentary – Our Small Country: This 2013 television documentary cites LDN for relief from symptoms associated with multiple sclerosis and fibromyalgia. Per MedScape and anecdotal reports, “about 15,297 patients, or 0.3% of the country’s population, was prescribed LDN by physicians following the airing of the documentary. Over the next year, there were dramatic drops in prescriptions for high-cost drugs used in the treatment of rheumatoid and seropositive arthritis, inflammatory bowel disease, epilepsy, psychotic conditions, and depression.”
In addition to the many benefits of LDN, MedScape further suggests that LDN’s relatively inexpensive cost (averaging $25-$65/month) further positions it as “a low-cost and safe alternative treatment for several chronic neurologic, rheumatologic, psychiatric, and gastrointestinal inflammatory conditions.”
To read the full MedScape article, click here.
To request an LDN prescription, click here.
Until next time!